Scholarlink

Background <p>Premature ovarian insufficiency (POI) is a prevalent reproductive endocrine disorder, with genetic pathogenesis remaining largely elusive. <i>SPATA22</i> is a known meiotic regulator in germ cells, while its function in ovarian somatic granulosa cells (GCs) and causal link to POI remain entirely uncharacterized.</p> Methods <p>Whole-exome sequencing (WES) was performed in 608 idiopathic POI patients, with Sanger sequencing validating the identified <i>SPATA22</i> variants in the affected pedigree. Pathogenicity and therapeutic potential were verified via in vivo phenotypic analysis of <i>Spata22</i><sup><i>+/−</i></sup> mice, in vitro functional assays of primary mouse GCs, oocyte-GCs co-culture, and in vitro fertilization (IVF) embryo development assays, with N-acetylcysteine (NAC) intervention.</p> Results <p>Two heterozygous pathogenic <i>SPATA22</i> variants were identified in a POI pedigree with four affected infertile individuals. <i>SPATA22</i> defects caused GCs dysfunction, accumulated DNA damage, oxidative stress, ovarian insufficiency, impaired fertility in mice. The antioxidant NAC effectively rescued GCs defects, and partially restored <i>Spata22</i><sup><i>+/−</i></sup> mice fertility, ovarian function, co-cultured oocyte competence and embryo development potential.</p> Conclusions <p>The present study identifies <i>SPATA22</i> as a causative gene for human POI, provides the first definitive demonstration of a non-canonical somatic function of <i>SPATA22</i> in GCs, and offers a promising therapeutic strategy for <i>SPATA22</i>-related POI.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

SPATA22 heterozygous variants drive premature ovarian insufficiency: mechanism of granulosa cells dysfunction and therapeutic potential of N-acetylcysteine (NAC) treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月7日

查看全文
  • Lingjin Xia,
  • Wenjing Zhang,
  • Miao Liu,
  • Yupei Shen,
  • Jian Zhang,
  • Difei Wang,
  • Fei Wang,
  • Zhaofeng Zhang,
  • Yushun Zhong,
  • Ya Huang,
  • Guihua Li,
  • Xin Wang,
  • Zhikai Wang,
  • Suying Liu,
  • Jing Du

摘要

Background

Premature ovarian insufficiency (POI) is a prevalent reproductive endocrine disorder, with genetic pathogenesis remaining largely elusive. SPATA22 is a known meiotic regulator in germ cells, while its function in ovarian somatic granulosa cells (GCs) and causal link to POI remain entirely uncharacterized.

Methods

Whole-exome sequencing (WES) was performed in 608 idiopathic POI patients, with Sanger sequencing validating the identified SPATA22 variants in the affected pedigree. Pathogenicity and therapeutic potential were verified via in vivo phenotypic analysis of Spata22+/− mice, in vitro functional assays of primary mouse GCs, oocyte-GCs co-culture, and in vitro fertilization (IVF) embryo development assays, with N-acetylcysteine (NAC) intervention.

Results

Two heterozygous pathogenic SPATA22 variants were identified in a POI pedigree with four affected infertile individuals. SPATA22 defects caused GCs dysfunction, accumulated DNA damage, oxidative stress, ovarian insufficiency, impaired fertility in mice. The antioxidant NAC effectively rescued GCs defects, and partially restored Spata22+/− mice fertility, ovarian function, co-cultured oocyte competence and embryo development potential.

Conclusions

The present study identifies SPATA22 as a causative gene for human POI, provides the first definitive demonstration of a non-canonical somatic function of SPATA22 in GCs, and offers a promising therapeutic strategy for SPATA22-related POI.